抄録
Proton pump inhibitors are commonly utilized for the treatment of gastric acid-related diseases, such as gastroesophageal reflux disease, peptic ulcer disease, and Helicobacter pylori infection, and for the prevention of low-dose aspirin or nonsteroidal anti-inflammatory drug-induced peptic ulcers. Vonoprazan is a first-in-class potassium-competitive acid blocker, which has distinct advantages compared to other conventional proton pump inhibitors in terms of the efficacy for acid suppression. Due to its strong gastric acid suppression capabilities, vonoprazan serves as an effective drug for the treatment of gastroesophageal reflux disease and H. pylori infection.
| 本文言語 | English |
|---|---|
| ページ（範囲） | 6-14 |
| ページ数 | 9 |
| ジャーナル | Journal of Neurogastroenterology and Motility |
| 巻 | 25 |
| 号 | 1 |
| DOI | |
| 出版ステータス | Published - 2019 1月 1 |
ASJC Scopus subject areas
- 臨床神経学
- 消化器病学